Previous Close | 197.70 |
Open | 191.76 |
Bid | 211.09 x 100 |
Ask | 211.95 x 200 |
Day's Range | 205.60 - 215.00 |
52 Week Range | 126.97 - 215.00 |
Volume | |
Avg. Volume | 274,212 |
Market Cap | 22.864B |
Beta (5Y Monthly) | 0.61 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
The consensus price target hints at a 27.8% upside potential for BeiGene (BGNE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
As the major U.S. stock indexes edged higher recently, investors are keeping a close eye on significant earnings reports and economic indicators that could influence market sentiment. Amid this cautious optimism, identifying undervalued stocks can be crucial for those looking to capitalize on potential discounts in the current market landscape.
Is it a good or bad thing when a stock experiences a golden cross technical event?